HC Wainwright Forecasts Lower Earnings for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities researchers at HC Wainwright reduced their Q2 2026 earnings per share (EPS) estimates for shares of TG Therapeutics in a note issued to investors on Monday, April 20th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will earn $0.20 per share for the quarter, down from their prior estimate of $0.27. The consensus estimate for TG Therapeutics’ current full-year earnings is $1.39 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q3 2026 earnings at $0.25 EPS, Q4 2026 earnings at $0.34 EPS, FY2027 earnings at $1.60 EPS, FY2028 earnings at $2.11 EPS, FY2029 earnings at $2.71 EPS and FY2030 earnings at $3.66 EPS.

Several other analysts have also recently commented on the company. Wall Street Zen cut TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. The Goldman Sachs Group raised their target price on TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Thursday, January 15th. JPMorgan Chase & Co. lowered their target price on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 29th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $50.00.

TG Therapeutics Stock Up 4.6%

Shares of TG Therapeutics stock opened at $36.96 on Tuesday. The company has a current ratio of 4.10, a quick ratio of 3.29 and a debt-to-equity ratio of 0.38. The business’s 50 day simple moving average is $31.02 and its 200-day simple moving average is $31.46. The stock has a market capitalization of $5.90 billion, a price-to-earnings ratio of 13.34 and a beta of 1.76. TG Therapeutics has a twelve month low of $25.28 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). The company had revenue of $192.57 million for the quarter, compared to analyst estimates of $192.15 million. TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The firm’s revenue for the quarter was up 78.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.15 earnings per share.

Hedge Funds Weigh In On TG Therapeutics

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of TG Therapeutics by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 15,841,002 shares of the biopharmaceutical company’s stock valued at $472,220,000 after purchasing an additional 319,703 shares during the period. State Street Corp raised its holdings in shares of TG Therapeutics by 4.7% in the 4th quarter. State Street Corp now owns 8,479,999 shares of the biopharmaceutical company’s stock worth $252,789,000 after purchasing an additional 379,380 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in TG Therapeutics by 35.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock valued at $61,144,000 after purchasing an additional 531,759 shares during the last quarter. Congress Asset Management Co. acquired a new stake in TG Therapeutics during the fourth quarter valued at approximately $57,307,000. Finally, Invesco Ltd. lifted its stake in TG Therapeutics by 47.1% during the fourth quarter. Invesco Ltd. now owns 1,609,815 shares of the biopharmaceutical company’s stock valued at $47,989,000 after purchasing an additional 515,481 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.